With revenues in excess of £368m in 2022 and a record of vigorous growth, Chiesi Limited. is the largest market within the Chiesi group.
For more than 80 years, Chiesi has developed innovative medicines and services for the world’s most vulnerable including developing medicines and services in neonatology, organ transplantation and rare diseases, alongside our treatments for respiratory conditions.
In the UK, Chiesi has a workforce of around 400 people employed directly or indirectly with chosen partners, who are based out of our head office in Manchester, the Research and Development centre in Chippenham, and across the UK as part of our experienced field-based teams.
As with every part of the Chiesi group, we embrace a shared set of values and a common code of ethical conduct. This demands the highest standards of reliability, transparency, and individual accountability, in everything we do. It emphasises the importance of collaborative working, putting people first and exchanging knowledge. Implicit in all of these values is a responsible attitude to meet high standards of social and environmental impact, and as of June 2019, Chiesi became a Certified B Corporation.
This certification recognises our part in a global movement for an inclusive, equitable and regenerative economy.
It is our people who are at the heart of what we do and what we achieve. We strive to create a culture that encourages innovation and allows everyone to flourish
Chiesi Farmaceutici S.p.A. is an international, research-based, biopharmaceutical group, based in Parma, Italy.
The Company was founded in 1935 and spans the globe, employing more than 6,500 people in 31 locations worldwide and selling its products in more than 100 countries1. With a turnover of 2 billion and 749 million euros, Chiesi is among the top 50 pharmaceutical companies in the world1.
Chiesi Limited. was established in 1999 with the acquisition of Trinity Pharmaceuticals (by Chiesi S.p.A), whose ethos, values and specialist expertise perfectly complemented those of the wider Chiesi group.
UK-CHI-2300573 October 2023